Operations & Technology

At BioConnetiX, we believe that evidence-based genetic medicine should be the standard of care, not the "luxury" care that it is today. We believe this so strongly, in fact, that our entire company was designed around this bold mission. This meant that we had to question everything we "traditionally" practiced in both laboratories and medical practices. What we realized was that science and medicine had incredible existing talent. While everyone else seemed to be coming up with a new lab or a new test or new medical practice, we thought: "Why don't we just build something that connects all of the existing great?"

The solution to managing cost and access within genetic-based care is in connecting existing resources

With this as our foundation, BioConnetiX developed software to connect existing resources, and then created process and operations protocols that could transform fragmented, costly laboratory testing into evidence-based, personalized care from a foundation in genetic science.

BioConnetiX is the first healthcare platform of its kind to harness physician, scientist, and operator specialization to comprehensively manage the entire supply chain in the continuum of laboratory care.

Our Partners | The Supply Chain for Genetic-Based Care

We partner with research institutions, molecular pathologists, scientists, and independent laboratories. These are the critical specialists required to supply precision medicine to the providers who deliver care. We catalyze change through extensive collaboration with our partners, leveraging repeatable processes, regimented operations, and sophisticated technology to make on-boarding and on-going participation efficient.

Partners integrate at their own pace and remain completely independent. Participation is open to any laboratory, pathology practice, or research institution who can meet our ambitious standards.

Systematic Processes | Consistent Results

Challenges in genetic laboratory testing are addressed both systematically and effectively – dramatically lowering costs while advancing the creation and adoption of comprehensive care based on individual genetic variation. Partner Laboratory Integration follows a regimented course beginning with proficiency-based assessment and advancing through 10 total outcomes-based levels of cost and utilization control, operational efficiency, collaboration, specialization, reporting, technology integration, and pathway-based workup and care management.

The Laboratory Operational Solution | INTEGRATE

Through the operational side of the platform, base testing needs are performed within an efficient networked system of laboratories proximate to patients, and new evidence-based protocols are commercialized economically through cooperative planning that includes capacity requirements, resource planning, location planning, and operator specialization.

Integrated laboratories are afforded access to offer all new tests, studies, protocols, and specialists within their existing network. They also become eligible to participate in validations for new EBM-based protocols and receive test volume from throughout the network for achieving scientific performance, operational turnaround, and cost benchmarks.

This allows healthcare systems and networks the ability to launch new evidence-based protocols simultaneously, dramatically accelerating access to care for patients while lowering the cost of testing. Aligned validations beget economies of scale through centralization of inventory & shipping management, as well as combined test menus, automated routing based on test need, and flexibility to manage complex evaluations and care plan needs with molecular pathologists or other specialists efficiently through a connected telehealth-type network.

Academics can innovate with the peace of the mind that evidence-based discoveries can be quickly and cost-effectively shared through a collaborative network. Pathologists can continue to discover while also practicing medicine through remote clinical workup and care plan creation for complex and specialized disease processes. Independent Laboratories can leverage their scientific talent to advance genomic medicine and focus on operations that lower the cost of care. Medical providers can provide personalized care with assurance and efficiency. Insurance Companies and other payors of healthcare can ensure expenditures are properly utilized and can leverage healthcare dollars to cover more genetic health services. Public Health systems can economically launch initiatives that improve population health. Healthcare systems and government networks can connect laboratories systematically and affordably to achieve economies of scale for large-scale testing needs as well as cost-effective access to specialty tests. Pharmaceutical companies can access better mechanisms for safely delivering new drugs and biologics with pharmacogenomic dose guidance.